Apersys Secures Series A Funding to Revolutionize Organ Perfusion Technology

Apersys AG, a pioneering Swiss medtech startup emerging from the innovative Liver4Life project incubated at the Wyss Zurich Translational Center, is thrilled to announce that it has successfully raised funding to further its mission in transforming organ transplantation. Although the specific amount raised remains undisclosed, this crucial financial support will enable the company to advance its cutting-edge perfusion system designed to tackle the pressing issue of organ shortages. With a multidisciplinary team comprised of surgeons, biologists, entrepreneurs, and engineers, Apersys is committed to revolutionizing the way organs are preserved and transported. The funding will be instrumental in accelerating the research and development of its state-of-the-art technology, which promises to enhance the viability of transplant organs and ultimately improve patient outcomes. By leveraging innovative approaches in perfusion technology, Apersys aims to not only extend the shelf-life of organs but also ensure that more patients have access to life-saving transplants. The backing of this funding serves as a testament to the growing recognition of the urgent need for solutions in the field of organ transplantation. Apersys AG is poised to make significant strides in this vital area of healthcare, reinforcing its position as a leader in the medtech space while addressing one of the most pressing medical challenges of our time. With this financing, Apersys looks forward to advancing its mission of ensuring that no one has to wait for a life-saving organ.